Paper Details

  1. Home
  2. Paper Details

Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen.

Author: AhnJae-Sook, AhnSeo-Yeon, JoJae-Cheol, JungSung-Hoon, KimHyeoung-Joon, KimMihee, KimSu-In, LeeJe-Jung, SongGa-Young, YangDeok-Hwan, YhimHo-Young

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluated the efficacy of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma (MM) receiving bortezomib, melphalan, and prednisone (VMP) therapy.
Paper Details　
Original Abstract of the Article :
Although survival outcomes of multiple myeloma (MM) have improved with the development of new and effective agents, infection remains the major cause of morbidity and mortality. Here, we evaluated the efficacy of levofloxacin prophylaxis (in a real-world setting) during bortezomib, melphalan, and pr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958375/

データ提供：米国国立医学図書館（NLM）

Levofloxacin Prophylaxis in Elderly Multiple Myeloma Patients

This study investigates the efficacy of [levofloxacin prophylaxis] in elderly patients with [newly diagnosed multiple myeloma (MM)] undergoing [bortezomib, melphalan, and prednisone (VMP) therapy]. The authors analyzed real-world data to assess the impact of levofloxacin on [infection rates] in this high-risk population. The study provides valuable information for clinicians in managing infection risk in elderly MM patients receiving VMP therapy.

Preventing Infections in Vulnerable Patients: Real-World Evidence for Prophylaxis

This research highlights the importance of [infection prevention] in vulnerable populations, particularly elderly patients with [multiple myeloma (MM)]. It's like building a fortress against a desert sandstorm, shielding these patients from the threats of infection. The study's findings provide real-world evidence for the efficacy of levofloxacin prophylaxis in this specific setting, offering valuable insights for clinical practice.

Navigating the Desert of Cancer Treatment: Infection Prevention Strategies

Imagine the challenges of navigating the desert of cancer treatment, facing the constant threat of infections. This research explores the use of levofloxacin prophylaxis in elderly patients with MM, offering a potential shield against the dangers of infection. The study's findings provide valuable insights into infection prevention strategies for this vulnerable population.

Dr. Camel's Conclusion

This real-world evidence study investigates the efficacy of levofloxacin prophylaxis in elderly MM patients receiving VMP therapy. It's like discovering a new oasis of protection in the desert of cancer treatment, offering valuable insights into preventing infections in this high-risk population.
Date :
  1. Date Completed n.d.
  2. Date Revised 2022-05-02
Further Info :

Pubmed ID

35197371

DOI: Digital Object Identifier

PMC8958375

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.